ClinicalTrials.Veeva

Menu

How Does YES Bar Affect Blood Glucose Levels?

E

Efforia, Inc

Status

Enrolling

Conditions

Blood Glucose Monitoring

Treatments

Other: YES Bar

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Curious to see if there is a sweet treat that doesn't spike your blood sugar (avoiding the energy crash, inflammation, and weight gain)? This study uses the Abbott Lingo CGM to see how your blood glucose levels responds to YES Bar-an all natural, gluten-free, plant-based bar that tastes like dessert. You'll track your levels before and after eating it to see if it fits into your metabolic health. (iOS Only)

Full description

This remotely administered decentralized trial is designed to rigorously evaluate the impact of Yes Bar on blood sugar levels in a real-world setting, utilizing the latest in continuous glucose monitoring technology provided by Abbott's Lingo CGM. The founder of Yes Bar initiated this study in response to numerous anecdotal reports suggesting that Yes Bar does not cause the blood sugar spikes typically associated with snack consumption. The objective is to move beyond these anecdotal experiences to gather solid, data-driven evidence regarding the metabolic effects of consuming Yes Bar.

Participants in this study will engage in a unique and personal exploration of their metabolic health by tracking their blood sugar levels in response to consuming Yes Bars. Utilizing the Abbott Lingo CGM, which currently is compatible only with the iPhone, participants will monitor their blood glucose response, enabling an individualized assessment of how Yes Bar integrates into their dietary habits and metabolic health.

This study is not solely for the purpose of marketing Yes Bars but aims to contribute valuable insights for participants themselves, providing them with concrete data on how their bodies respond to Yes Bars. By participating in at least four individual experiments with Yes Bar over a period of 7 days, participants will not only contribute to a broader understanding of the snack's metabolic impact but will also receive a $17 gift card as a token of appreciation for their contribution to this scientific inquiry.

The primary goal of this trial is to scientifically assess the blood sugar response following the consumption of Yes Bar, leveraging the capabilities of the Abbott Lingo CGM. This endeavor also seeks to evaluate the feasibility of using consumer-grade continuous blood glucose monitors in dietary impact studies, in collaboration with Efforia. Through this study, we aim to bridge the gap between anecdotal evidence and empirical data, potentially transforming the way Yes Bar is marketed and perceived in the context of a healthy diet.

This study is not only pivotal for marketing strategies but, more importantly, serves as an opportunity for participants to gain insights into their own metabolic health, offering a personalized perspective on how Yes Bar might help in avoiding the undesirable blood sugar fluctuations that lead to energy crashes and cravings. Participants will emerge from this study with personalized data that could inform their dietary choices and perhaps introduce them to a new, metabolically friendly snack option.

Enrollment

100 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Can read and understand English.
  • US resident.
  • Willing and able to follow the requirements of the protocol.

Trial design

Primary purpose

Health Services Research

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Single arm where participants act as their own control
Experimental group
Description:
Single arm where participants act as their own control
Treatment:
Other: YES Bar

Trial contacts and locations

1

Loading...

Central trial contact

Matthew Amsden

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems